Early Biomarker Detection for Cardiac and Tumor Diseases via CLIA Method
Early Biomarker Detection for Cardiac and Tumor Diseases via CLIA Method – Powered by RealyTech Kits from Amindo Biologics
Introduction
Early detection is the cornerstone of effective disease management, particularly for life-threatening conditions such as cardiovascular diseases and cancer. With advances in diagnostic technology, Chemiluminescence Immunoassay (CLIA) has emerged as a highly sensitive and specific method for identifying disease biomarkers. Amindo Biologics, a leading supplier in the IVD domain, proudly offers RealyTech CLIA Kits, ensuring accurate, early-stage biomarker detection for both cardiac and tumor-related diseases.
What is CLIA?
Chemiluminescence Immunoassay (CLIA) is an advanced immunoassay technique that utilizes a chemical reaction to produce light, which is measured to determine the presence of specific biomarkers. Compared to ELISA, CLIA offers:
- Higher sensitivity and specificity
- Faster turnaround time
- Wider dynamic range
- Automation compatibility
This makes CLIA particularly effective for early disease detection, where biomarker levels may be very low.
Cardiac Biomarker Detection
Cardiovascular diseases remain one of the leading causes of mortality worldwide. RealyTech CLIA kits available through Amindo Biologics allow early identification of cardiac disorders through precise detection of critical biomarkers such as:
- Troponin I/T (cTnI/cTnT): Gold-standard markers for myocardial infarction.
- CK-MB (Creatine Kinase MB): Supports diagnosis of acute myocardial injury.
- Myoglobin (Myo): Rapid-release marker useful for early detection.
- NT-proBNP (N-terminal pro B-type Natriuretic Peptide): Crucial for heart failure diagnosis.
- hs-CRP (High-Sensitivity C-Reactive Protein): Indicates inflammation and the risk of cardiac events.
Early detection of these markers can significantly improve prognosis by enabling timely intervention and treatment.
Tumor Biomarker Detection
For oncology, early detection is directly linked to survival rates. RealyTech’s CLIA-based tumor marker kits assist in the diagnosis and monitoring of various cancers:
- AFP (Alpha-fetoprotein): Liver cancer marker
- CEA (Carcinoembryonic Antigen): Marker for colorectal and other gastrointestinal cancers
- CA125: Widely used in ovarian cancer screening
- CA19-9: Pancreatic and gastrointestinal cancer marker
- PSA (Prostate-Specific Antigen): Key marker for prostate cancer
- CA15-3: Breast cancer monitoring
- NSE (Neuron Specific Enolase): Used in small cell lung cancer detection
These kits provide robust performance with excellent reproducibility, ensuring clinicians have reliable data for diagnosis and monitoring.
Why Choose RealyTech CLIA Kits from Amindo Biologics?
Amindo Biologics is a trusted supplier of high-quality diagnostic solutions across India. The RealyTech brand CLIA kits offer:
- CE and ISO certified products
- Compatibility with standard CLIA analysers
- Ready-to-use reagents for simplified workflow
- An extensive biomarker panel across multiple disease areas
- Prompt technical support and logistics across India
Whether for hospitals, diagnostic laboratories, or research institutions, these kits are designed to meet the highest standards of diagnostic accuracy and reliability.
Conclusion
In the battle against cardiac and tumor diseases, early detection is a game-changer. With the superior sensitivity and speed of the CLIA method, and the reliable quality of RealyTech kits supplied by Amindo Biologics, healthcare providers are better equipped to diagnose early, treat faster, and improve patient outcomes.
Partner with Amindo Biologics today and bring cutting-edge diagnostics to your lab.
